Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 14 art units • 17 examiners • 0 of 17 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Wake Forest University Health Sciences has 15 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 15 examiners and 14 art units, indicating that the docket is broadly distributed across examiners while one art unit handles more than one matter. This structure limits the usefulness of a single examiner-focused strategy.
LI, WENHAN is the busiest identified examiner, with 1 pending matter. Counsel should therefore emphasize consistent portfolio records and technical support while reviewing art-unit practices where assignments repeat. Each response still requires individualized treatment because the examiner assignments are otherwise distinct.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (18%) |
| §103 only | 6 (35%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 7 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, WENHAN | 1 | — | — |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
| ARON, KIMBERLY A | 1 | 54.7% | +34.3% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| MOLOYE, TITILAYO | 1 | 62.3% | +48.3% |
| LANDAU, SHARMILA GOLLAMUDI | 1 | 11.1% | +4.6% |
| GU, QINHUA | 1 | 76.2% | +27.1% |
| MILLER, SERENITY A | 1 | 68.5% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18603721 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES | DONOHUE, SEAN R | 28d overdue |
| 19181471 | Bioink Compositions and Methods for 3D Printing Of Vascularized Tissue Constructs | LI, WENHAN | — |
| 18833026 | METHOD FOR DETERMINATION OF MUTATED FORM OF MUCIN-1 PROTEIN IN A BIOLOGICAL SAMPLE | OGUNTADE, ELIZABETH BISOLA | — |
| 18645616 | Rotator Cuff Therapy Using Muscle Fiber Fragments | CANDELARIA, JULIANA IRENE | — |
| 18544936 | COMPOSITIONS, CELL CONSTRUCTS, AND METHODS OF MAKING AND USING THE SAME | MOLOYE, TITILAYO | — |
| 18538015 | SPONTANEOUSLY BEATING CARDIAC ORGANOID CONSTRUCTS AND INTEGRATED BODY-ON-CHIP APPARATUS CONTAINING THE SAME | LANDAU, SHARMILA GOLLAMUDI | — |
| 18287491 | MINIMALLY INVASIVE APPENDECTOMY DEVICE AND METHOD | MILLER, SERENITY A | — |
| 18037708 | VECTORS, SYSTEMS AND METHODS FOR EUKARYOTIC GENE EDITING | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18603721 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES | DONOHUE, SEAN R | 28d overdue |
| 18289875 | GENE THERAPY FOR DENT DISEASE | GU, QINHUA | 60d |
| 18794181 | AMNIOTIC MEMBRANE POWDER AND ITS USE IN WOUND HEALING AND TISSUE ENGINEERING CONSTRUCTS | COFFA, SERGIO | — |
| 18833026 | METHOD FOR DETERMINATION OF MUTATED FORM OF MUCIN-1 PROTEIN IN A BIOLOGICAL SAMPLE | OGUNTADE, ELIZABETH BISOLA | — |
| 18741884 | SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE | ARON, KIMBERLY A | — |
| 18544936 | COMPOSITIONS, CELL CONSTRUCTS, AND METHODS OF MAKING AND USING THE SAME | MOLOYE, TITILAYO | — |
| 18287491 | MINIMALLY INVASIVE APPENDECTOMY DEVICE AND METHOD | MILLER, SERENITY A | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1634 | 2 |
| 1632 | 2 |
| 1614 | 1 |
| 1658 | 1 |
| 1677 | 1 |
| 1618 | 1 |
| 1653 | 1 |
| 3771 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19181471 | Bioink Compositions and Methods for 3D Printing Of Vascularized Tissue Constructs | LI, WENHAN | 1614 | §102§103§112 | Non-Final OA | — | Pending | Apr 17, 2025 |
| 18794181 | AMNIOTIC MEMBRANE POWDER AND ITS USE IN WOUND HEALING AND TISSUE ENGINEERING CONSTRUCTS | COFFA, SERGIO | 1658 | §103DP | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18833026 | METHOD FOR DETERMINATION OF MUTATED FORM OF MUCIN-1 PROTEIN IN A BIOLOGICAL SAMPLE | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18741884 | SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE | ARON, KIMBERLY A | 1633 | §103 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18645616 | Rotator Cuff Therapy Using Muscle Fiber Fragments | CANDELARIA, JULIANA IRENE | 1634 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18603721 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES | DONOHUE, SEAN R | 1618 | §103§112 | Final Rejection | 28d overdue | Pending | Mar 13, 2024 |
| 18544936 | COMPOSITIONS, CELL CONSTRUCTS, AND METHODS OF MAKING AND USING THE SAME | MOLOYE, TITILAYO | 1632 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18538015 | SPONTANEOUSLY BEATING CARDIAC ORGANOID CONSTRUCTS AND INTEGRATED BODY-ON-CHIP APPARATUS CONTAINING THE SAME | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18289875 | GENE THERAPY FOR DENT DISEASE | GU, QINHUA | 1633 | §103 | Final Rejection | 60d | Pending | Nov 07, 2023 |
| 18287491 | MINIMALLY INVASIVE APPENDECTOMY DEVICE AND METHOD | MILLER, SERENITY A | 3771 | §102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18276812 | ENGINEERED EXTRACELLULAR VESICLES AND THEIR USES | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | 9d | Pending | Aug 10, 2023 |
| 18037708 | VECTORS, SYSTEMS AND METHODS FOR EUKARYOTIC GENE EDITING | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §101§103DP | Non-Final OA | — | Pending | May 18, 2023 |
| 18157759 | CALIBRATION OF SOLID-STATE SENSORS | DO, AN H | 2853 | §101§102 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 17607995 | MINIMAL PROCESSING METHOD FOR DECELLULARIZATION OF TISSUES | MONTANARI, DAVID A | 1632 | §103 | Non-Final OA | — | Pending | Nov 01, 2021 |
| 17048879 | A MEDICAL DEVICE FOR DEPLOYING A CATHETER THAT CAN BE OPERATED WITH A SINGLE HAND, AND A METHOD | SMALE, AVERY E | 3783 | §103 | Final Rejection | 24d overdue | Pending | Oct 19, 2020 |
| 16921287 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE | SITTON, JEHANNE SOUAYA | 1682 | §101§112DP | Non-Final OA | — | Pending | Jul 06, 2020 |
| 16079813 | NON-MIGRATING STENT DEVICES AND METHODS | HU, ANN M | 3774 | §103 | Final Rejection | — | Pending | Aug 24, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWake Forest University Health Sciences has 17 pending office actions as of October 2026, spread across 14 art units and 17 examiners.
Wenhan Li has the most, with 1 of Wake Forest University Health Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
